Financial ResilienceSoleno Therapeutics has significant cash reserves expected to support the VYKAT XR launch and potentially reach cash flow breakeven.
Market LaunchThe U.S. launch of VYKAT XR is progressing well, with prescriptions delivered and broad engagement with payers to establish patient access.
Regulatory ApprovalThe European Medicines Agency validated Soleno Therapeutics' application for approval of diazoxide choline tablets, which are already approved in the U.S., suggesting a strong chance for European approval.